Comparative Pharmacology
Head-to-head clinical analysis: EMTRICITABINE versus EMTRICITABINE AND TENOFOVIR ALAFENAMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EMTRICITABINE versus EMTRICITABINE AND TENOFOVIR ALAFENAMIDE.
EMTRICITABINE vs EMTRICITABINE AND TENOFOVIR ALAFENAMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that is phosphorylated to emtricitabine triphosphate, which competes with the natural substrate deoxycytidine-5'-triphosphate and incorporates into viral DNA, causing chain termination. Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor (NtRTI) that is converted to tenofovir diphosphate, which inhibits HIV-1 reverse transcriptase by competing with the natural substrate deoxyadenosine-5'-triphosphate and incorporating into DNA, leading to chain termination.
200 mg orally once daily, typically in combination with other antiretroviral agents.
One tablet (200 mg emtricitabine / 25 mg tenofovir alafenamide) orally once daily with food.
None Documented
None Documented
Clinical Note
moderateEmtricitabine + Ribavirin
"Emtricitabine may increase the hepatotoxic activities of Ribavirin."
Clinical Note
moderateLamivudine + Emtricitabine
"The risk or severity of adverse effects can be increased when Lamivudine is combined with Emtricitabine."
Clinical Note
moderateGanciclovir + Emtricitabine
"The risk or severity of adverse effects can be increased when Ganciclovir is combined with Emtricitabine."
Clinical Note
moderateValganciclovir + Emtricitabine
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Emtricitabine: terminal half-life ~10 hours (clinical context: supports once-daily dosing). Tenofovir alafenamide: terminal half-life ~0.5 hours (prodrug), but active tenofovir diphosphate intracellular half-life >60 hours in PBMCs (clinical context: supports once-daily dosing due to long intracellular persistence).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Emtricitabine: primarily renal (86% unchanged) via glomerular filtration and active tubular secretion. Tenofovir alafenamide: metabolism to tenofovir, then renal (70-80% unchanged) via glomerular filtration and active tubular secretion; <1% fecal.
Category C
Category A/B
Antiretroviral, NRTI
NRTI
"The risk or severity of adverse effects can be increased when Valganciclovir is combined with Emtricitabine."